Amin Khan, PhD is the Executive Vice President and Head of R&D at Icosavax, Inc., and Chief Science Advisor for the mRNA Program at Afrigen Biologics. He has more than 30 years’ experience in vaccine and pharmaceutical R&D, including senior scientific and executive leadership roles at Eli Lilly, Novartis and GlaxoSmithKline. He has guided scientific and technical teams to develop novel vaccines for infectious diseases, including targets for RSV, influenza, meningitis, group B streptococcus, S. aureus, COPD, CMV, herpes zoster and SARS-Cov-2, and has contributed to the licensure of four vaccines. Dr. Khan and his teams have developed products utilizing a broad range of enabling technologies including recombinant proteins, viral vectors and nucleic acids. As Chief Science Officer, Human Health at GreenLight Biosciences, he led the company’s efforts to progress its first vaccine asset from immunogen design to clinical readiness in 12 months while building the company’s human health expertise and capabilities. Prior to this, Dr Khan held roles of increasing responsibility at GSK including VP, Global Head of Technical R&D and serving as a member of the Vaccines R&D leadership team. Dr.Khan holds a PhD in Pharmaceutical Sciences from the University of Nottingham, UK.